Ausgewählte Datenmodelle

Sie müssen eingeloggt sein, um mehrere Datenmodelle auszuwählen und diese herunterzuladen oder zu analysieren.

37 Suchergebnisse.
Relevanz Bewertung Neue zuerst Alte zuerst

ICHOM Lung Cancer - Follow-up - Clinical Form

- 20.09.21 - 1 Formular, 8 Itemgruppen, 64 Datenelemente, 1 Sprache
Itemgruppen: Administrative data, Degree of health, Baseline tumor factors, Treatment Factors, Treatment Variables, Acute complications of treatment, Survival, Quality of death
ICHOM Lung cancer data collection Version 2.3.1 Revised: April 10th, 2017 International Consortium for Health Outcomes Measurement (ICHOM), Source: http://www.ichom.org/ Notice: This work was conducted using resources from ICHOM, the International Consortium for Health Outcomes Measurement (www.ICHOM.org). The content is solely the responsibility of the authors and does not necessarily represent the official views of ICHOM. For Lung Cancer, the following conditions and treatment approaches (or interventions) are covered by our Standard Set. Conditions: Small Cell and Non-Small Cell Lung Cancer Treatment Approaches: Surgery | Radiotherapy | Chemotherapy | Targeted Therapy | Immunotherapy | Other This document contains Follow-up - Clinical Form. It includes different points in time: After treatment, After surgery, Update at least annually, 1 year post initiation of treatment and Tracked ongoing annually for life (when hospital is able to track this ongoing). Collecting Patient-Reported Outcome Measures: European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30). European Organization for Research and Treatment of Cancer Quality of Life Lung Cancer-Specific Questionnaire (EORTC QLQ-LC13). Both are free for all health care organizations, but a license is needed for use. http:// groups.eortc.be/qol/eortc-qlq-c30 is the official distribution site for EORTC QLQ-C30 and EORTC QLQ-LC13 questionnaires. Therefore only the total score will be included in this version of the standard set. Publication: Mak KS, van Bommel AC, Stowell C, et al. Defining a standard set of patient-centred outcomes for lung cancer. Eur Respir J. 2016;48(3):852–860. doi:10.1183/13993003.02049-2015 For this standard set ICHOM was supported by the Alliance of Dedicated Cancer Centers. For this version of the standard set, semantic annotation with UMLS CUIs has been added.

quality management ADT-radiotherapy cancer - quality management

- 27.09.21 - 1 Formular, 4 Itemgruppen, 35 Datenelemente, 2 Sprachen
Itemgruppen: Patientendaten, Patientenadresse, Bestrahlung, Nebenwirkungen nach CTC
base-dataset from ADT - radiotherapy, ODM derived from http://www.tumorzentren.de/tl_files/dokumente/adt_basis.pdf

HIS radiotherapy form prostate cancer - HIS

- 07.08.13 - 1 Formular, 7 Itemgruppen, 31 Datenelemente, 2 Sprachen
Itemgruppen: Admininstrative Daten, Tumordiagnose, Strahlentherapie, Tumortherapie allgemein, Bestrahlung, Therapiebeurteilung, Nebenwirkungen nach CTC (Common Toxicity Criteria)
HIS form from Soarian. Urologie Erlangen" with friendly permission of the urology Erlangen (Prof. Wullich) and the medical informatics department Erlangen (PD Dr. Bürkle)

HIS radiotherapy form prostate cancer - HIS

- 15.05.13 - 1 Formular, 7 Itemgruppen, 31 Datenelemente, 2 Sprachen
Itemgruppen: Admininstrative Daten, Tumordiagnose, Strahlentherapie, Tumortherapie allgemein, Bestrahlung, Therapiebeurteilung, Nebenwirkungen nach CTC (Common Toxicity Criteria)
HIS radiotherapy form prostate cancer

Hypofractionation for Breast Cancer NCT01948726 - Eligibility Criteria

- 15.06.19 - 1 Formular, 2 Itemgruppen, 14 Datenelemente, 1 Sprache
Itemgruppen: Inclusion Criteria, Exclusion Criteria
Hypofractionation With Simultaneous Integrated Boost for Early Breast Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT01948726 Hypofractionation with simultaneous integrated boost has been investigated in a few trials and appears to be safe and feasible with less lung toxicity in smaller studies. Investigators initiated this multicenter phase II prospective trial to analyse acute toxicity of hypofractionation with simultaneous integrated boost in patients with early breast cancer under the hypothesis that the ratio of patients with acute radiogenic toxicity Grad II according NCI-CTCAE amounts maximum 20%.

Eligibility Prostate Cancer NCT00619515

- 10.06.17 - 1 Formular, 1 Itemgruppe, 21 Datenelemente, 1 Sprache
Itemgruppe: Criteria
Stereotactic Radiation Therapy in Treating Patients With Prostate Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00619515

Eligibility Breast Cancer NCT00897702

- 22.02.17 - 1 Formular, 2 Itemgruppen, 12 Datenelemente, 1 Sprache
Itemgruppen: Inclusion Criteria, Exclusion Criteria
Molecular Mechanisms of Clinical Resistance to Targeted Therapy Among Patients With Breast Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00897702

Hypofractionated Radiotherapy in Prostate Cancer NCT01368055 - Eligibility Criteria

- 15.03.21 - 1 Formular, 2 Itemgruppen, 10 Datenelemente, 1 Sprache
Itemgruppen: Inclusion Criteria, Exclusion Criteria
Hypofractionated Proton Radiation Therapy for Low and Intermediate Risk Prostate Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT01368055

Lung Cancer RADIATION THERAPY NCT00020709 - RADIATION THERAPY FORM LUNG CARCINOMA NCT00020709

- 08.05.15 - 1 Formular, 2 Itemgruppen, 42 Datenelemente, 1 Sprache
Itemgruppen: Header, TREATMENT INFORMATION
LUNG CARCINOMA RADIATION THERAPY FORM S0023: Combination Chemo Plus RT With or Without Gefitinib in Treating Patients With Unresectable Stage III NSCLC NCT00020709 Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=9E343E83-5FEB-119F-E034-080020C9C0E0

HistoScanning-based Brachytherapy in Prostate Cancer NCT01409876 - Eligibility Criteria

- 22.05.19 - 1 Formular, 2 Itemgruppen, 11 Datenelemente, 1 Sprache
Itemgruppen: Inclusion Criteria, Exclusion Criteria
Phase II trial looking at the feasibility of HistoScanning-based dose-painting image-guided interstitial brachytherapy in non-metastatic prostate cancer; ODM derived from: https://clinicaltrials.gov/show/NCT01409876

SABR in High Risk Prostate Cancer (SATURN) NCT01953055 - Eligibility Criteria

- 22.05.19 - 1 Formular, 2 Itemgruppen, 10 Datenelemente, 1 Sprache
Itemgruppen: Inclusion Criteria, Exclusion Criteria
Phase II Study of Stereotactic Ablative Radiotherapy Including Regional Lymph Node Irradiation for Patients With High Risk Prostate Cancer (SATURN); ODM derived from: https://clinicaltrials.gov/show/NCT01953055

Initial Follow-up Form Prostate Cancer (NCT00288080)

- 07.01.15 - 1 Formular, 7 Itemgruppen, 66 Datenelemente, 1 Sprache
Itemgruppen: Header, Vital Status, Progression, PROSTATE: PSA MEASUREMENTS, Treatment Schedule (LHRH Agonist), TREATMENT SCHEDULE (ORAL ANTIANDROGEN), Non-protocol Therapy
RTOG 0521 FO: Radiation Therapy Oncology Group Phase III Randomized Study of Localized, High-Risk Prostate Cancer Initial Follow-up Form Hormone Therapy and Radiation Therapy or Hormone Therapy and Radiation Therapy Followed by Docetaxel and Prednisone in Treating Patients With Localized Prostate Cancer NCT00288080 Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=0CB07BEA-FAB7-6032-E044-0003BA3F9857

Hilfe

Benötigen Sie Hilfe bei der Suche? Um mehr Details zu erfahren und die Suche effektiver nutzen zu können schauen Sie sich doch das entsprechende Video auf unserer Tutorial Seite an.

Zum Video